These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 28074905)

  • 1. MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway.
    Fang C; Chen YX; Wu NY; Yin JY; Li XP; Huang HS; Zhang W; Zhou HH; Liu ZQ
    Sci Rep; 2017 Jan; 7():40384. PubMed ID: 28074905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
    Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
    EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM; Ge F; Chen XJ; Tang C; Ma J
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation.
    Zhang Y; Yu JJ; Tian Y; Li ZZ; Zhang CY; Zhang SF; Cao LQ; Zhang Y; Qian CY; Zhang W; Zhou HH; Yin JY; Liu ZQ
    Oncotarget; 2015 Sep; 6(28):25441-51. PubMed ID: 26213845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsa_circ_0096157 silencing suppresses autophagy and reduces cisplatin resistance in non-small cell lung cancer by weakening the Nrf2/ARE signaling pathway.
    Lu H; Kong J; Cai S; Huang H; Luo J; Liu L
    Mol Biol Rep; 2024 Jun; 51(1):703. PubMed ID: 38822881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1.
    Cheng R; Lu C; Zhang G; Zhang G; Zhao G
    Oncol Rep; 2017 Apr; 37(4):2129-2136. PubMed ID: 28350100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
    Huang J; Lin C; Dong H; Piao Z; Jin C; Han H; Jin D
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):663-672. PubMed ID: 33030583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-3195 inhibits non-small cell lung cancer malignant behaviors along with cisplatin resistance through targeting PFKFB4.
    Chen R; Gao X; Shen Y
    Cell Mol Biol (Noisy-le-grand); 2024 Jul; 70(7):73-78. PubMed ID: 39097893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-29b-3p targetedly regulates VEGF to inhibit tumor progression and cisplatin resistance through Nrf2/HO-1 signaling pathway in non-small cell lung cancer.
    Sun Z; Ren M; Niu J; Tang G; Li Y; Kong F; Song X
    Environ Toxicol; 2024 Jul; 39(7):3956-3966. PubMed ID: 38587027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy.
    Ma Y; Yuwen D; Chen J; Zheng B; Gao J; Fan M; Xue W; Wang Y; Li W; Shu Y; Xu Q; Shen Y
    Int J Nanomedicine; 2019; 14():8121-8132. PubMed ID: 31632022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
    Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
    BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC.
    Wang X; Chen X; Meng Q; Jing H; Lu H; Yang Y; Cai L; Zhao Y
    Sci Rep; 2015 Dec; 5():17618. PubMed ID: 26620926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer.
    Jiao P; Hou J; Yao M; Wu J; Ren G
    Biomed Pharmacother; 2019 Sep; 117():109164. PubMed ID: 31252267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
    Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
    BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription.
    Liu Y; Wang X; Li W; Xu Y; Zhuo Y; Li M; He Y; Wang X; Guo Q; Zhao L; Qiang L
    Oncogene; 2020 Nov; 39(45):6893-6905. PubMed ID: 32978517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway.
    Xu L; Xu Y; Yang M; Li J; Xu F; Chen BL
    BMC Pulm Med; 2020 Oct; 20(1):266. PubMed ID: 33059643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
    Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
    Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC.
    Jiang Z; Yin J; Fu W; Mo Y; Pan Y; Dai L; Huang H; Li S; Zhao J
    PLoS One; 2014; 9(4):e94639. PubMed ID: 24722426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.